• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

解读人类肿瘤生态系统对溶瘤病毒的易感性。

Deciphering permissivity of human tumor ecosystems to oncolytic viruses.

作者信息

Schoeps Benjamin, Lauer Ulrich M, Elbers Knut

机构信息

ViraTherapeutics GmbH, Rum, Austria.

Department of Medical Oncology and Pneumology, Virotherapy Center Tübingen (VCT), Medical University Hospital, Tübingen, Germany.

出版信息

Oncogene. 2025 May;44(16):1069-1077. doi: 10.1038/s41388-025-03357-5. Epub 2025 Mar 27.

DOI:10.1038/s41388-025-03357-5
PMID:40148688
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11996678/
Abstract

Effective cancer therapy involves initiation of a tumor-specific immune response. Consequently, the interest in oncolytic viruses (OV) capable of triggering immunogenic cell death has sparked in recent years. However, the common use of pre-clinical models that fail to mirror patient tumor ecosystems (TES) hinders clinical translation. Here, we provide a condensed view on the intricate interplay between several aspects of TES and OV action and discuss these considerations in the view of recently developed pre-clinical human model systems. Given the urgent demand for innovative cancer treatments, the purpose of this review is to highlight the so-far overlooked complex impact of the tumor microenvironment (TME) on OV permissivity, with the intent to provide a foundation for future, more effective pre-clinical studies.

摘要

有效的癌症治疗涉及启动肿瘤特异性免疫反应。因此，近年来人们对能够引发免疫原性细胞死亡的溶瘤病毒（OV）产生了兴趣。然而，未能反映患者肿瘤生态系统（TES）的临床前模型的普遍使用阻碍了临床转化。在这里，我们简要概述了TES的几个方面与OV作用之间的复杂相互作用，并结合最近开发的临床前人类模型系统讨论了这些考虑因素。鉴于对创新癌症治疗的迫切需求，本综述的目的是强调肿瘤微环境（TME）对OV易感性迄今为止被忽视的复杂影响，旨在为未来更有效的临床前研究提供基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8560/11996678/2325cec2335c/41388_2025_3357_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8560/11996678/c0b877996d0a/41388_2025_3357_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8560/11996678/f3d49f1c2d42/41388_2025_3357_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8560/11996678/ccf60252f885/41388_2025_3357_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8560/11996678/9f91cb37df31/41388_2025_3357_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8560/11996678/2325cec2335c/41388_2025_3357_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8560/11996678/c0b877996d0a/41388_2025_3357_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8560/11996678/f3d49f1c2d42/41388_2025_3357_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8560/11996678/ccf60252f885/41388_2025_3357_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8560/11996678/9f91cb37df31/41388_2025_3357_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8560/11996678/2325cec2335c/41388_2025_3357_Fig5_HTML.jpg

相似文献

1
Deciphering permissivity of human tumor ecosystems to oncolytic viruses.解读人类肿瘤生态系统对溶瘤病毒的易感性。
Oncogene. 2025 May;44(16):1069-1077. doi: 10.1038/s41388-025-03357-5. Epub 2025 Mar 27.
2
Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy.利用溶瘤免疫疗法点燃肿瘤微环境中的火焰。
EBioMedicine. 2018 May;31:17-24. doi: 10.1016/j.ebiom.2018.04.020. Epub 2018 Apr 23.
3
Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.溶瘤病毒对肿瘤微环境的免疫转换：细小病毒 H-1PV 案例研究。
Front Immunol. 2019 Aug 7;10:1848. doi: 10.3389/fimmu.2019.01848. eCollection 2019.
4
Comparison of differences in immune cells and immune microenvironment among different kinds of oncolytic virus treatments.比较不同种类溶瘤病毒治疗方法之间免疫细胞和免疫微环境的差异。
Front Immunol. 2024 Nov 11;15:1494887. doi: 10.3389/fimmu.2024.1494887. eCollection 2024.
5
Oncolytic viruses as cancer therapeutics: From mechanistic insights to clinical translation.溶瘤病毒作为癌症治疗手段：从机制洞察到临床转化
Mol Ther. 2025 May 7;33(5):2217-2228. doi: 10.1016/j.ymthe.2025.03.035. Epub 2025 Mar 25.
6
Oncolytic Virotherapy and the Tumor Microenvironment.溶瘤病毒治疗与肿瘤微环境。
Adv Exp Med Biol. 2017;1036:157-172. doi: 10.1007/978-3-319-67577-0_11.
7
Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses.简明综述：利用溶瘤病毒靶向肿瘤干细胞及其支持微环境。
Stem Cells. 2019 Jun;37(6):716-723. doi: 10.1002/stem.3004. Epub 2019 Apr 9.
8
Immune landscape and response to oncolytic virus-based immunotherapy.免疫景观与基于溶瘤病毒免疫治疗的反应
Front Med. 2024 Jun;18(3):411-429. doi: 10.1007/s11684-023-1048-0. Epub 2024 Mar 8.
9
Multidirectional Strategies for Targeted Delivery of Oncolytic Viruses by Tumor Infiltrating Immune Cells.肿瘤浸润免疫细胞介导的溶瘤病毒靶向递呈的多向策略。
Pharmacol Res. 2020 Nov;161:105094. doi: 10.1016/j.phrs.2020.105094. Epub 2020 Aug 12.
10
The evolving landscape of oncolytic virus immunotherapy: combinatorial strategies and novel engineering approaches.溶瘤病毒免疫疗法的发展态势：联合策略与新型工程方法
Med Oncol. 2025 May 2;42(6):190. doi: 10.1007/s12032-025-02746-w.

引用本文的文献

1
Navigating the Purification Process: Maintaining the Integrity of Replication-Competent Enveloped Viruses.探索纯化过程：维持有复制能力的包膜病毒的完整性
Vaccines (Basel). 2025 Apr 23;13(5):444. doi: 10.3390/vaccines13050444.

本文引用的文献

1
VSV drives CD8 T cell-mediated tumour regression through infection of both cancer and non-cancer cells.VSV 通过感染癌细胞和非癌细胞来驱动 CD8 T 细胞介导的肿瘤消退。
Nat Commun. 2024 Nov 15;15(1):9933. doi: 10.1038/s41467-024-54111-6.
2
Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures.用于患者来源的胰腺癌培养物中溶瘤病毒治疗疗效的生物标志物筛选。
EBioMedicine. 2024 Jul;105:105219. doi: 10.1016/j.ebiom.2024.105219. Epub 2024 Jun 27.
3
Further knowledge and developments in resistance mechanisms to immune checkpoint inhibitors.
免疫检查点抑制剂耐药机制的进一步认识和发展。
Front Immunol. 2024 Jun 5;15:1384121. doi: 10.3389/fimmu.2024.1384121. eCollection 2024.
4
Tumor-killing viruses score rare success in late-stage trial.杀伤肿瘤病毒在晚期试验中取得罕见成功。
Science. 2023 Dec 8;382(6675):1101-1102. doi: 10.1126/science.adn3528. Epub 2023 Dec 7.
5
Integrating innate and adaptive immunity in oncolytic virus therapy.将先天免疫和适应性免疫整合到溶瘤病毒治疗中。
Trends Cancer. 2024 Feb;10(2):135-146. doi: 10.1016/j.trecan.2023.09.012. Epub 2023 Oct 23.
6
World's First Long-Term Colorectal Cancer Model by 3D Bioprinting as a Mechanism for Screening Oncolytic Viruses.世界首个通过3D生物打印构建的长期结直肠癌模型，作为一种筛选溶瘤病毒的机制
Cancers (Basel). 2023 Sep 26;15(19):4724. doi: 10.3390/cancers15194724.
7
The challenge of making the right choice: patient avatars in the era of cancer immunotherapies.做出正确选择的挑战：癌症免疫疗法时代的患者化身。
Front Immunol. 2023 Aug 10;14:1237565. doi: 10.3389/fimmu.2023.1237565. eCollection 2023.
8
Study of Oncolytic Virus Preservation and Formulation.溶瘤病毒保存与制剂研究
Pharmaceuticals (Basel). 2023 Jun 5;16(6):843. doi: 10.3390/ph16060843.
9
Micro-engineering and nano-engineering approaches to investigate tumour ecosystems.微工程和纳米工程方法研究肿瘤生态系统。
Nat Rev Cancer. 2023 Sep;23(9):581-599. doi: 10.1038/s41568-023-00593-3. Epub 2023 Jun 23.
10
Defects in intratumoral arginine metabolism attenuate the replication and therapeutic efficacy of oncolytic myxoma virus.肿瘤内精氨酸代谢缺陷削弱了溶瘤性牛痘病毒的复制和治疗效果。
J Immunother Cancer. 2023 Jun;11(6). doi: 10.1136/jitc-2022-006388.